You are here :
Home
Healthcare
Biotechnology
Life Sciences Research
Drug Discovery
In vitro drug discovery
Global Cell based assays Market Research Report
- Report Code: CE 1000
- Publish Date: Upcoming
Cell based assays and Next Generation Sequencer (NGS), Metabolomics, Biobanking/Biopreservation, RNA Interference, Biomarkers, Stem cell research, Next Generation Sequencing (NGS) and High throughput screening adds up to total In vitro drug discovery market.
Cell based assays can be segmented by Submarkets and Technologies. Submarkets of this market are Next Generation Sequencer (NGS), Metabolomics, Biobanking/Biopreservation, RNA Interference, Biomarkers, Stem cell research, Next Generation Sequencing (NGS) and High content analysis/Screening. Technologies of this market are NGS Platforms/Consumables/Services and Genomics.
Cell based assays can be segmented by Submarkets and Technologies. Submarkets of this market are Next Generation Sequencer (NGS), Metabolomics, Biobanking/Biopreservation, RNA Interference, Biomarkers, Stem cell research, Next Generation Sequencing (NGS) and High content analysis/Screening. Technologies of this market are NGS Platforms/Consumables/Services and Genomics.
Key Questions Answered
- What are market estimates and forecasts; which of Cell based assays markets are doing well and which are not?
- This reports provides most granular segmentation on Next Generation Sequencer (NGS), Metabolomics, Biobanking/Biopreservation and RNA Interference.
- This report provides market sizing and forecast for the Cell based assays market. It also provides market sizing and forecast along with the drivers/inhibitors/opportunity analysis for each of the micro markets.
- Global Cell based assays companies
- Manufacturing Companies
- Traders, distributors, and suppliers
- Governmental and research organizations
- Associations and industry bodies
- Technology providers
What makes our report unique?
Audience for this report
1 Introduction
1.1 Analyst Insights
1.2 Market Definitions
1.3 Market Segmentation & Aspects Covered
1.4 Research Methodology
2 Executive Summary
3 Market Overview
4 By Submarkets
4.1 Next Generation Sequencer (NGS)
4.2 Metabolomics
4.3 Biobanking/Biopreservation
4.4 RNA Interference
4.5 Biomarkers
4.6 Stem cell research
4.7 Next Generation Sequencing (NGS)
4.8 High content analysis/Screening
5 By Technologies
5.1 NGS Platforms/Consumables/Services
5.2 Genomics
Please fill in the form below to receive a free copy of the Summary of this Report
Custom Market Research Services
We will customize the research for you, in case the report listed above does not
meet with your exact requirements. Our custom research will comprehensively cover
the business information you require to help you arrive at strategic and profitable
business decisions.
Please visit http://www.micromarketmonitor.com/custom-research-services.html to specify your custom Research Requirement
Please visit http://www.micromarketmonitor.com/custom-research-services.html to specify your custom Research Requirement
| PRODUCT TITLE | PUBLISHED | |
|---|---|---|
|
|
High content analysis/Screening The global High Content Screening market was valued at $380.31 million in 2013 and is expected to reach $646.59 million by 2018, growing at a CAGR of 11.2% from 2013 to 2018. High Content Screening market segmentation primarily based on product types, the market is categorized into instruments, consumables, software, and services. Based on applications, the high content screening market is segmented into primary and secondary screening, target identification and validation, toxicity studies, and compound profiling. Among the various end users of high content screening, pharmaceutical and biotechnology companies lead the market. Major players in the market include Thermo Fisher Scientific (U.S.), Molecular Devices (U.S.), PerkinElmer (U.S.), and GE Healthcare (U.K), among others |
Upcoming |
|
|
North American High Content analysis/Screening The North American High Content Screening market was valued at $161.8 million in 2013 and is expected to reach $280.7 million by 2018, growing at a CAGR of 11.7% from 2013 to 2018. High Content Screening market segmentation primarily based on product types, the market is categorized into instruments (Imaging and Analysis HCS Systems, Flow Cytometers), consumables (Reagents and Assay kits, Microplates and other consumables) , software, and services. Based on applications, the high content screening market is segmented into primary and secondary screening, target identification and validation, toxicity studies, and compound profiling. Among the various end users of high content screening, pharmaceutical and biotechnology companies lead the market. Major players in the market include Thermo Fisher Scientific (U.S.), Molecular Devices (U.S.), PerkinElmer (U.S.), and GE Healthcare (U.K), Olympus (Japan), Life Technologies (U.S.), EMD Millipore (Germany), BD Bioscience (U.S.), Definiens AG (Germany), Yokogawa Electric Corporation (Japan), and TTP Labtech (U.S). |
Upcoming |
|
|
European High content analysis/Screening The European High Content Screening market was valued at $124.29 million in 2013 and is expected to reach $207.9 million by 2018, growing at a CAGR of 10.6% from 2013 to 2018. High Content Screening market segmentation primarily based on product types, the market is categorized into instruments (Imaging and Analysis HCS Systems, Flow Cytometers), consumables (Reagents and Assay kits, Microplates and other consumables) , software, and services. Based on applications, the high content screening market is segmented into primary and secondary screening, target identification and validation, toxicity studies, and compound profiling. Among the various end users of high content screening, pharmaceutical and biotechnology companies lead the market. Major players in the market include Thermo Fisher Scientific (U.S.), Molecular Devices (U.S.), PerkinElmer (U.S.), and GE Healthcare (U.K), Olympus (Japan), Life Technologies (U.S.), EMD Millipore (Germany), BD Bioscience (U.S.), Definiens AG (Germany), Yokogawa Electric Corporation (Japan), and TTP Labtech (U.S). |
Upcoming |
|
|
Asian High content analysis/Screening The Asian High Content Screening market was valued at $55.75 million in 2013 and is expected to reach $101.74 million by 2018, growing at a CAGR of 12.8% from 2013 to 2018.High Content Screening market segmentation primarily based on product types, the market is categorized into instruments (Imaging and Analysis HCS Systems, Flow Cytometers), consumables (Reagents and Assay kits, Microplates and other consumables) , software, and services. Based on applications, the high content screening market is segmented into primary and secondary screening, target identification and validation, toxicity studies, and compound profiling. Among the various end users of high content screening, pharmaceutical and biotechnology companies lead the market. Major players in the market include Thermo Fisher Scientific (U.S.), Molecular Devices (U.S.), PerkinElmer (U.S.), and GE Healthcare (U.K), Olympus (Japan), Life Technologies (U.S.), EMD Millipore (Germany), BD Bioscience (U.S.), Definiens AG (Germany), Yokogawa Electric Corporation (Japan), and TTP Labtech (U.S). |
Upcoming |
4 reports |
Show
Cell based assays
